Aileron Therapeutics (NASDAQ:ALRN) Price Target Raised to $19.00 at LADENBURG THALM/SH SH

Aileron Therapeutics (NASDAQ:ALRN) had its price objective hoisted by LADENBURG THALM/SH SH from $9.00 to $19.00 in a report released on Thursday morning, Benzinga reports. The brokerage currently has a buy rating on the stock.

Aileron Therapeutics Stock Up 17.6 %

ALRN stock opened at $5.00 on Thursday. The company has a market capitalization of $24.45 million, a P/E ratio of -1.48 and a beta of 2.22. The company has a 50-day simple moving average of $5.40 and a 200 day simple moving average of $3.60. Aileron Therapeutics has a fifty-two week low of $1.01 and a fifty-two week high of $7.42.

Institutional Investors Weigh In On Aileron Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Renaissance Technologies LLC lifted its holdings in Aileron Therapeutics by 65.5% in the third quarter. Renaissance Technologies LLC now owns 190,691 shares of the company’s stock worth $39,000 after purchasing an additional 75,500 shares during the period. Envestnet Asset Management Inc. lifted its holdings in Aileron Therapeutics by 52.9% in the 3rd quarter. Envestnet Asset Management Inc. now owns 184,022 shares of the company’s stock valued at $38,000 after acquiring an additional 63,651 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Aileron Therapeutics by 23.2% in the 1st quarter. Geode Capital Management LLC now owns 54,799 shares of the company’s stock valued at $68,000 after acquiring an additional 10,311 shares during the last quarter. Sigma Planning Corp acquired a new stake in Aileron Therapeutics in the 4th quarter valued at about $51,000. Finally, Texas Capital Bank Wealth Management Services Inc acquired a new stake in Aileron Therapeutics in the 4th quarter valued at about $48,000. Institutional investors and hedge funds own 90.89% of the company’s stock.

About Aileron Therapeutics

Aileron Therapeutics, Inc operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial.